Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.

2.50
Hdl Handle:
http://hdl.handle.net/10541/82062
Title:
Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Authors:
Parkinson, Craig; Trainer, Peter J
Abstract:
Growth hormone receptor (GHR) dimerization is a prerequisite to the generation of growth hormone (GH) action. Pegvisomant is a GHR antagonist that has been designed to bind to the GHR at the cell surface and hence block this process. Initial studies suggest that pegvisomant is a highly effective antagonist of GH action in patients with acromegaly. The blockade of GH action, rather than the inhibition of pituitary GH secretion, represents a novel concept in the medical management of acromegaly. In this review, the design, efficacy, challenges and future role of pegvisomant are discussed.
Affiliation:
Department of Endocrinology, Christie Hospital, Manchester, UK.
Citation:
Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly. 2000, 10 Suppl B:S119-23 Growth Horm. IGF Res.
Journal:
Growth Hormone & IGF Research
Issue Date:
Apr-2000
URI:
http://hdl.handle.net/10541/82062
PubMed ID:
10984267
Type:
Article
Language:
en
ISSN:
1096-6374
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorParkinson, Craig-
dc.contributor.authorTrainer, Peter J-
dc.date.accessioned2009-09-22T11:51:40Z-
dc.date.available2009-09-22T11:51:40Z-
dc.date.issued2000-04-
dc.identifier.citationPegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly. 2000, 10 Suppl B:S119-23 Growth Horm. IGF Res.en
dc.identifier.issn1096-6374-
dc.identifier.pmid10984267-
dc.identifier.urihttp://hdl.handle.net/10541/82062-
dc.description.abstractGrowth hormone receptor (GHR) dimerization is a prerequisite to the generation of growth hormone (GH) action. Pegvisomant is a GHR antagonist that has been designed to bind to the GHR at the cell surface and hence block this process. Initial studies suggest that pegvisomant is a highly effective antagonist of GH action in patients with acromegaly. The blockade of GH action, rather than the inhibition of pituitary GH secretion, represents a novel concept in the medical management of acromegaly. In this review, the design, efficacy, challenges and future role of pegvisomant are discussed.en
dc.language.isoenen
dc.subject.meshAcromegaly-
dc.subject.meshAnimals-
dc.subject.meshAntibody Formation-
dc.subject.meshBinding Sites-
dc.subject.meshDimerization-
dc.subject.meshFemale-
dc.subject.meshHaplorhini-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshModels, Biological-
dc.subject.meshRats-
dc.subject.meshReceptors, Somatotropin-
dc.subject.meshSignal Transduction-
dc.titlePegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital, Manchester, UK.en
dc.identifier.journalGrowth Hormone & IGF Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.